Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Texas

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Risk Management

For decades, general health and science information has served as the foundation for public understanding of medical treatments and their associated risks. This legacy framework emphasizes broad awareness of therapeutic benefits while acknowledging potential adverse effects in a population-level context. Within this tradition, the focus remains on informed consent and the balance between clinical efficacy and patient safety, without delving into specialized mechanisms or individual case specifics. As this general health perspective evolves, it becomes necessary to address more targeted concerns that arise from specific therapeutic exposures. One such area involves the use of disease-modifying therapies in chronic conditions, where long-term treatment introduces distinct risk profiles. In particular, exposure to certain biologic agents has been linked to an increased likelihood of opportunistic infections, including progressive multifocal leukoencephalopathy (PML). This shift from general health education to occupational exposure concern requires careful consideration of how patients and providers navigate the implications of sustained drug therapy. The transition from broad health literacy to focused risk management is especially relevant when evaluating legal and regulatory frameworks. For individuals who have experienced adverse outcomes following treatment, understanding the timeline for seeking recourse becomes critical. This pivot from general awareness to specific exposure scenarios sets the stage for examining jurisdictional statutes that govern claims related to therapeutic complications.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed the disease even in the absence of other immunosuppressive conditions. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers, patients, and pharmacies to enroll and comply with specific monitoring and reporting requirements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, visual changes, and speech difficulties. These symptoms overlap with those of multiple sclerosis relapses, making early diagnosis challenging. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the range of neurological symptoms that may be reported by patients on Tysabri.

Mechanism of PML Development and Prognosis

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JCV in the brain. Under normal conditions, JCV is controlled by the immune system; when immune cell trafficking is blocked, JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. For patients who develop PML after Tysabri treatment, the prognosis is poor. The boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment options are limited and primarily involve supportive care, plasma exchange to accelerate Tysabri clearance, and, in some cases, antiviral therapy such as mirtazapine or mefloquine, though evidence for efficacy is limited.

Legal Considerations and Statute of Limitations in Texas

From a legal perspective, patients in Texas who have been harmed by Tysabri-associated PML may have claims based on inadequate warnings. The adequacy of the Tysabri label is a central issue. The boxed warning and the TOUCH program were implemented after Tysabri was temporarily withdrawn from the market in 2005 due to PML cases. However, plaintiffs may argue that the warnings were insufficient to inform patients and physicians of the true magnitude of risk, particularly regarding the cumulative risk over time and the limitations of risk stratification. The label identifies anti-JCV antibody status, treatment duration, and prior immunosuppressant use as risk factors, but it does not provide precise quantitative risk estimates for individual patients. Furthermore, the label instructs physicians to consider these factors in the context of expected benefit, which may leave room for interpretation. The statute of limitations for personal injury claims in Texas is generally two years from the date the injury is discovered or should have been discovered with reasonable diligence. For PML, the date of discovery may be the date of diagnosis, which can occur months or years after the initial exposure to Tysabri. The timeline between Tysabri exposure and documented harm is variable; PML can develop after as few as a few doses or after several years of treatment. The label notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This extended latency period can complicate statute of limitations calculations, as the injury may not become apparent until well after the treatment period ends. Patients who have been diagnosed with PML after Tysabri treatment should consult with an attorney experienced in pharmaceutical litigation to evaluate their potential claims. The attorney will need to review medical records to establish the diagnosis, the timing of Tysabri exposure, and the presence of any risk factors. The attorney will also assess whether the prescribing physician and the patient were adequately warned of the PML risk and whether the TOUCH program was properly followed. In Texas, claims may be brought under theories of product liability, including failure to warn and design defect, as well as negligence and medical malpractice if the prescribing physician failed to monitor appropriately.

Summary of Tysabri PML Risk and Legal Recourse

In summary, Tysabri carries a well-documented risk of PML, a devastating brain infection that is often fatal or leads to severe disability. The FDA label identifies specific risk factors and mandates monitoring and reporting through the TOUCH program. For patients in Texas who have developed PML, the statute of limitations is typically two years from discovery, but the variable latency period between exposure and harm requires careful factual analysis. Legal evaluation should focus on the adequacy of warnings, compliance with the TOUCH program, and the specific circumstances of the patient's treatment and diagnosis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Texas?

The statute of limitations for personal injury claims in Texas is generally two years from the date the injury is discovered or should have been discovered with reasonable diligence. For PML, the date of discovery is typically the date of diagnosis, which can occur months or years after Tysabri exposure. Because PML can develop after a variable latency period, it is crucial to consult an attorney promptly to evaluate the specific timeline.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors are used to stratify risk, but the label does not provide precise quantitative estimates for individual patients.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.